Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
Holding LFCR?
Track your performance easily
LFCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.68 - $8.90
Previous CloseN/A
Volume140.23K
Average Volume (3M)312.73K
Market Cap
$234.00M
Enterprise Value$417.37M
Total Cash (Recent Filing)$6.00M
Total Debt (Recent Filing)$46.03M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Apr 02, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding37,025,330
10 Day Avg. Volume198,871
30 Day Avg. Volume312,732
Standard Deviation0.20
R-Squared0.07
Alpha-0.00122
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.79
Price to Cash Flow (P/CF)-9.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.78
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit9.97
Enterprise Value/Ebitda-29.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering3
Lifecore Biomedical News
PremiumCompany Announcements
Lifecore Biomedical’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Lifecore Biomedical Reports Q2 Fiscal 2025 ResultsBulls Say, Bears Say
Bulls Say
Business DevelopmentThe company disclosed that it has identified 50 new business development opportunities, which includes significant multinational pharmaceutical representation of around 30%.
Financial FlexibilityThe sale of Lifecore's excess capital equipment is seen as a smart move because it provides $17 million in cash and enhances financial flexibility.
Growth PotentialLifecore Biomedical aims to achieve 12% average annual revenue growth over the next three to four years and 25% or better EBITDA margins by the end of that mid-term window.
Bears Say
Cash FlowFree cash flow is expected to be negative with projections of only breaking even in the future, raising concerns about the company's liquidity.
Financial PerformanceLifecore is facing a significant challenge with a highly leveraged balance sheet, holding approximately $180.1 million in debt and only around $9.5 million in cash.
ValuationThe stock's high valuation at 22x EV/EBITDA makes it difficult to justify a premium valuation, resulting in a recommendation to maintain a MARKET PERFORM investment rating.
---
Ownership Overview
29.33% Insiders
5.51% Mutual Funds
0.13% Other Institutional Investors
57.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LFCR FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was $3.68 and its highest was $8.90 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is $234.00M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is Apr 02, 2025 which is in 62 days.
How were Lifecore Biomedical’s earnings last quarter?
Lifecore Biomedical released its earnings results on Jan 02, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.04.
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Overvalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate is -0.14.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,025,330 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Lifecore Biomedical reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went up 14.414%.
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in LFCR
---
Lifecore Biomedical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
LFCR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 19.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $97.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.59%
12-Months-Change
Fundamentals
Return on Equity
-29.58%
Trailing 12-Months
Asset Growth
3.89%
Trailing 12-Months
Company Description
Lifecore Biomedical
Landec Corp. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Curation Foods, Lifecore, and Others. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Clara, CA.
---
LFCR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
While Lifecore demonstrated notable growth in revenue, gross profit, and adjusted EBITDA, alongside successful financing and credit restructuring, the net loss and increased expenses present challenges that must be addressed. However, the strategic initiatives and leadership changes indicate a positive trajectory for future growth.Read More>---
LFCR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Abbott Laboratories
―
Baxter International
―
Becton Dickinson
―
Haemonetics
―
Medtronic
―
Best Analysts Covering LFCR
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
+3.28%
assigned a buy rating 20 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +3.28% per trade.
---